Alkermes Launches Brilliance Phase 3 Program for Narcolepsy Treatment with Alixorexton

Alkermes plc announces a significant development in its research pipeline with the launch of the Brilliance phase 3 program, which targets narcolepsy treatment through its oral orexin 2 receptor agonist, alixorexton.

This program is a continuation of earlier positive findings from phase 1 and phase 2 trials, positioning Alkermes to establish a stronghold in the growing sleep-disorder market. Having already acquired Breakthrough Therapy designation for narcolepsy type 1, the company is set to make considerable advancements in the therapeutic landscape for sleep disorders.

The Brilliance program aims not only to advance clinical evaluation but also to solidify Alkermes' long-term vision in this therapeutic area.

In addition to its efforts in narcolepsy, Alkermes continues to focus on expanding its portfolio in central nervous system (CNS) disorders, enhancing its capabilities in developing innovative therapies for conditions with high unmet needs.

This strategic move not only reinforces Alkermes' commitment to research and development but also strengthens its competitive position in the pharmaceuticals market, particularly within the niche of specialized CNS treatments.